Related references
Note: Only part of the references are listed.Biomarkers and risk factors for the early prediction of immune-related adverse events: a review
Ying Zhang et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2022)
A novel mouse model for checkpoint inhibitor-induced adverse events
Kieran Adam et al.
PLOS ONE (2021)
Establishing a model system for evaluating CAR T cell therapy using dogs with spontaneous diffuse large B cell lymphoma
M. Kazim Panjwani et al.
ONCOIMMUNOLOGY (2020)
Summary of a workshop on preclinical and translational safety assessment of CD3 bispecifics
Cris Kamperschroer et al.
JOURNAL OF IMMUNOTOXICOLOGY (2020)
Logic-Gated ROR1 Chimeric Antigen Receptor Expression Rescues T Cell-Mediated Toxicity to Normal Tissues and Enables Selective Tumor Targeting
Shivani Srivastava et al.
CANCER CELL (2019)
Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell-recruiting Antibody Optimized for Cytotoxicity and Cytokine Release
Christina L. Zuch de Zafra et al.
CLINICAL CANCER RESEARCH (2019)
Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer
Guoyun Zhu et al.
SCIENTIFIC REPORTS (2019)
GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts
Rosalie M. Sterner et al.
BLOOD (2019)
Bispecific T-cell engagers: Towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety
Diego Ellerman
METHODS (2019)
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Jerome Galon et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Human hematopoietic stem cell maintenance and myeloid cell development in next-generation humanized mouse models
Trisha R. Sippel et al.
BLOOD ADVANCES (2019)
Development of a vaccine model to track the CD8-specific response in Mauritius cynomolgus monkey
Richard Graveline et al.
CANCER RESEARCH (2019)
Development of a new patient-derived xenograft humanised mouse model to study human-specific tumour microenvironment and immunotherapy
Yue Zhao et al.
GUT (2018)
Preclinical Models in Chimeric Antigen Receptor-Engineered T-Cell Therapy
Elizabeth Louise Siegler et al.
HUMAN GENE THERAPY (2018)
Strengths andWeaknesses of Pre-Clinical Models for Human Melanoma Treatment: Dawn of Dogs' Revolution for Immunotherapy
Giuseppina Barutello et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells
Margherita Norelli et al.
NATURE MEDICINE (2018)
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Chimeric Antigen Receptor T Cell-Mediated Neurotoxicity in Nonhuman Primates
Agne Taraseviciute et al.
CANCER DISCOVERY (2018)
Checkpoint Blockade Reverses Anergy in IL-13Rα2 Humanized scFv-Based CAR T Cells to Treat Murine and Canine Gliomas
Yibo Yin et al.
MOLECULAR THERAPY-ONCOLYTICS (2018)
Tumor-immune profiling of murine syngeneic tumor models as a framework to guide mechanistic studies and predict therapy response in distinct tumor microenvironments
Jong W. Yu et al.
PLOS ONE (2018)
Nonclinical safety evaluation of two distinct second generation variants of anti-CTLA4 monoclonal antibody, ipilimumab, in monkeys
Karen D. Price et al.
MOLECULAR CANCER THERAPEUTICS (2018)
A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo (vol 31, pg 1743, 2017)
S. Hipp et al.
LEUKEMIA (2017)
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Severe cytokine release syndrome in a patient receiving PD-1-directed therapy
Seth J. Rotz et al.
PEDIATRIC BLOOD & CANCER (2017)
Experimental animal modeling for immuno-oncology
Qi-Xiang Li et al.
PHARMACOLOGY & THERAPEUTICS (2017)
Humanized mouse model supports development, function, and tissue residency of human natural killer cells
Dietmar Herndler-Brandstetter et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
An FDA oncology analysis of CD3 bispecific constructs and first-in-human dose selection
Haleh Saber et al.
REGULATORY TOXICOLOGY AND PHARMACOLOGY (2017)
In vitro assays supporting the safety assessment of immunomodulatory monoclonal antibodies
Frank R. Brennan et al.
TOXICOLOGY IN VITRO (2017)
CD3xPDL1 bi-specific T cell engager (BiTE) simultaneously activates T cells and NKT cells, kills PDL1+ tumor cells, and extends the survival of tumor-bearing humanized mice
Lucas A. Horn et al.
ONCOTARGET (2017)
Cancer immunotherapy: Historical Perspective of a Clinical Revolution and emerging Preclinical Animal Models
William K. Decker et al.
FRONTIERS IN IMMUNOLOGY (2017)
A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma
Naoya Maekawa et al.
SCIENTIFIC REPORTS (2017)
Checkpoint Inhibitor-Induced Colitis: A New Type of Inflammatory Bowel Disease?
Madeline Bertha et al.
ACG CASE REPORTS JOURNAL (2017)
Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?
Joseph M. Ryan et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2016)
Application of a MABEL Approach for a T-Cell-Bispecific Monoclonal Antibody
Sherri Dudal et al.
JOURNAL OF IMMUNOTHERAPY (2016)
An FDA oncology analysis of immune activating products and first-in-human dose selection
Haleh Saber et al.
REGULATORY TOXICOLOGY AND PHARMACOLOGY (2016)
Determination of the starting dose in the first-in-human clinical trials with monoclonal antibodies: a systematic review of papers published between 1990 and 2013
Hoon Young Suh et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2016)
Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2-/-IL2Rγnull Immunodeficient Mice
Miguel F. Sanmamed et al.
CANCER RESEARCH (2015)
Enhancing the Functional Maturity of Induced Pluripotent Stem Cell-Derived Human Hepatocytes by Controlled Presentation of Cell-Cell Interactions In Vitro
Dustin R. Berger et al.
HEPATOLOGY (2015)
Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy
Mizuki Nishino et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: Preclinical activity and safety in nonhuman primates
Gurunadh R. Chichili et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody
Ross Stewart et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Safety of Targeting ROR1 in Primates with Chimeric Antigen Receptor-Modified T Cells
Carolina Berger et al.
CANCER IMMUNOLOGY RESEARCH (2015)
CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330
Christina Krupka et al.
BLOOD (2014)
Cytokine release assays: Current practices and future directions
D. Finco et al.
CYTOKINE (2014)
T-cell-dependent antibody responses in the rat: Forms and sources of keyhole limpet hemocyanin matter
H. Lebrec et al.
JOURNAL OF IMMUNOTOXICOLOGY (2014)
Expression of PD-L1 on Canine Tumor Cells and Enhancement of IFN-γ Production from Tumor-Infiltrating Cells by PD-L1 Blockade
Naoya Maekawa et al.
PLOS ONE (2014)
Disruption of the immune-checkpoint VISTA gene imparts a proinflammatory phenotype with predisposition to the development of autoimmunity
Li Wang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
The T-cell-dependent antibody response assay in nonclinical studies of pharmaceuticals and chemicals: Study design, data analysis, interpretation
Herve Lebrec et al.
REGULATORY TOXICOLOGY AND PHARMACOLOGY (2014)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
Different Adaptations of IgG Effector Function in Human and Nonhuman Primates and Implications for Therapeutic Antibody Treatment
Max Warncke et al.
JOURNAL OF IMMUNOLOGY (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice
Taku Okazaki et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
Humanized Mouse Model of Ovarian Cancer Recapitulates Patient Solid Tumor Progression, Ascites Formation, and Metastasis
Richard B. Bankert et al.
PLOS ONE (2011)
Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells
D. Eastwood et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
Practical approaches to dose selection for first-in-human clinical trials with novel biopharmaceuticals
Jay Tibbitts et al.
REGULATORY TOXICOLOGY AND PHARMACOLOGY (2010)
Use of pharmacokinetic/pharmacodynamic modelling for starting dose selection in first-in-human trials of high-risk biologics
Balaji M. Agoram
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Safety Assessment and Dose Selection for First-in-Human Clinical Trials With Immunomodulatory Monoclonal Antibodies
P. Y. Muller et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies
Patrick Y. Muller et al.
CURRENT OPINION IN BIOTECHNOLOGY (2009)
PD-1 Blockade in Rhesus Macaques: Impact on Chronic Infection and Prophylactic Vaccination
Adam C. Finnefrock et al.
JOURNAL OF IMMUNOLOGY (2009)
Adenovirus Vector-Induced Immune Responses in Nonhuman Primates: Responses to Prime Boost Regimens
Nia Tatsis et al.
JOURNAL OF IMMUNOLOGY (2009)
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rγnull mice
Michelle R. Simpson-Abelson et al.
JOURNAL OF IMMUNOLOGY (2008)
Fc gamma receptors as regulators of immune responses
Falk Nimmerjahn et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Programmed death 1 ligand (PD-L) 1 and PD-L2 limit autoimmune kidney disease: Distinct roles
Julia Menke et al.
JOURNAL OF IMMUNOLOGY (2007)
On the anticipation of the human dose in first-in-man trials from preclinical and prior clinical information in early drug development
P. J. Lowe et al.
XENOBIOTICA (2007)
IgG fc receptor III homologues in nonhuman primate species: Genetic characterization and ligand interactions
Kenneth A. Rogers et al.
JOURNAL OF IMMUNOLOGY (2006)
Reconstitution of a functional human immune system in immunodeficient mice through combined human fetal thymus/liver and CD34+ cell transplantation
Ping Lan et al.
BLOOD (2006)
Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4
Kimberly E. Beck et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Development of functional human blood and immune systems in NOD/SCID/IL2 receptor γ chainnull mice
F Ishikawa et al.
BLOOD (2005)
Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis
AD Salama et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
A replication competent adenovirus 5 host range mutant-simian immunodeficiency virus (SIV) recombinant priming/subunit protein boosting vaccine regimen induces broad, persistent SIV-speeific cellular immunity to dominant and subdominant epitopes in Mamu-A*01 Rhesus macaques
N Malkevitch et al.
JOURNAL OF IMMUNOLOGY (2003)
Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance
A Sanchez-Fueyo et al.
NATURE IMMUNOLOGY (2003)
Share Paper
